Literature DB >> 11401912

Urinary estrogen metabolites and mammographic parenchymal patterns in postmenopausal women.

E Riza1, I dos Santos Silva, B De Stavola, H L Bradlow, D W Sepkovic, D Linos, A Linos.   

Abstract

It has been hypothesized that women who metabolize their endogenous estrogens predominantly via 16(alpha)-hydroxylation rather than via 2-hydroxylation and, as a result, have a low ratio of 2-hydroxyestrone (2-OHE1):16(alpha)-hydroxyestrone (16(alpha)-OHE1) are at an increased risk of breast cancer. Epidemiological evidence in support of this hypothesis is scarce and mostly based on measurements made after the onset of the disease. To gain insight into the role of these metabolites in the etiology of breast cancer, we assessed their relationship with high-density Wolfe mammographic parenchymal patterns (P2/DY), a recognized indicator of risk of this tumor. The study was nested within a large cross-sectional survey on determinants of mammographic patterns carried out in a population-based breast screening program in Northern Greece. Urinary levels of 2-OHE1 and 16(alpha)-OHE1 were measured in a random sample of 70 postmenopausal women with P2/DY mammographic patterns and in a random sample of 70 women with N1 mammographic patterns, individually matched to the P2/DY women on year of birth, years since menopause and date of urine collection. Women with a P2/DY pattern had, on average, 58% higher levels of 2-OHE1 (P = 0.002) and 15% higher levels of 16(alpha)-OHE1 (P = 0.37) than those with an N1 pattern. The ratio of 2-OHE1:16(alpha)-OHE1 was 35% higher (P = 0.005) in women with a P2/DY pattern. Women in the highest one-third of this ratio were six times more likely to have a P2/DY pattern than those in the lowest one-third after adjusting for potential confounders (prevalence odds ratio, 6.2; 95% CI, 1.7-22.9; test for linear trend, P = 0.002). These findings seem to suggest that a high, rather than a low, 2-OHE1:16(alpha)-OHE1 ratio may be associated with an increase in breast cancer risk at postmenopausal ages, unless the pathway through which estrogen metabolites may affect breast cancer risk is unrelated to mammographic parenchymal patterns.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401912

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  18 in total

Review 1.  Estrogens in the breast tissue: a systematic review.

Authors:  Lusine Yaghjyan; Graham A Colditz
Journal:  Cancer Causes Control       Date:  2011-02-01       Impact factor: 2.506

2.  The relation of urinary estrogen metabolites with mammographic densities in premenopausal women.

Authors:  Gertraud Maskarinec; Sreang Heak; Yukiko Morimoto; Laurie Custer; Adrian A Franke
Journal:  Cancer Epidemiol       Date:  2012-04-25       Impact factor: 2.984

3.  Dairy intake in relation to breast and pubertal development in Chilean girls.

Authors:  Audrey J Gaskins; Ana Pereira; Daiana Quintiliano; John A Shepherd; Ricardo Uauy; Camila Corvalán; Karin B Michels
Journal:  Am J Clin Nutr       Date:  2017-04-05       Impact factor: 7.045

4.  Estrogen metabolism and mammographic density in postmenopausal women: a cross-sectional study.

Authors:  Barbara J Fuhrman; Louise A Brinton; Ruth M Pfeiffer; Xia Xu; Timothy D Veenstra; Barbara E Teter; Celia Byrne; Cher M Dallal; Maddalena Barba; Paola C Muti; Gretchen L Gierach
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

5.  Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.

Authors:  Mellissa Yong; Stephen M Schwartz; Charlotte Atkinson; Karen W Makar; Sushma S Thomas; Katherine M Newton; Erin J Aiello Bowles; Victoria L Holt; Wendy M Leisenring; Johanna W Lampe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

Review 6.  Endocrine disruption via estrogen receptors that participate in nongenomic signaling pathways.

Authors:  Cheryl S Watson; Yow-Jiun Jeng; Jutatip Guptarak
Journal:  J Steroid Biochem Mol Biol       Date:  2011-02-12       Impact factor: 4.292

7.  A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.

Authors:  Cynthia A Thomson; H H Sherry Chow; Betsy C Wertheim; Denise J Roe; Alison Stopeck; Gertraud Maskarinec; Maria Altbach; Pavani Chalasani; Chuan Huang; Meghan B Strom; Jean-Philippe Galons; Patricia A Thompson
Journal:  Breast Cancer Res Treat       Date:  2017-05-30       Impact factor: 4.872

8.  Associations between endogenous sex hormone levels and mammographic and bone densities in premenopausal women.

Authors:  Mellissa Yong; Charlotte Atkinson; Katherine M Newton; Erin J Aiello Bowles; Frank Z Stanczyk; Kim C Westerlind; Victoria L Holt; Stephen M Schwartz; Wendy M Leisenring; Johanna W Lampe
Journal:  Cancer Causes Control       Date:  2009-03-12       Impact factor: 2.506

9.  Relationship of serum estrogens and metabolites with area and volume mammographic densities.

Authors:  Gretchen L Gierach; Deesha A Patel; Roni T Falk; Ruth M Pfeiffer; Berta M Geller; Pamela M Vacek; Donald L Weaver; Rachael E Chicoine; John A Shepherd; Amir Pasha Mahmoudzadeh; Jeff Wang; Bo Fan; Sally D Herschorn; Xia Xu; Timothy Veenstra; Barbara Fuhrman; Mark E Sherman; Louise A Brinton
Journal:  Horm Cancer       Date:  2015-03-11       Impact factor: 3.869

Review 10.  Non-genomic effects of xenoestrogen mixtures.

Authors:  René Viñas; Yow-Jiun Jeng; Cheryl S Watson
Journal:  Int J Environ Res Public Health       Date:  2012-07-31       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.